Fosun Pharma eyes HK to float subsidiary
Shanghai Fosun Pharmaceutical Group is looking to spin off subsidiary Yaneng Bioscience with a listing in Hong Kong, according to a filing with the city’s stock exchange.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts